Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Geron Corporation

< Previous 1 2 3 4 Next >
Geron to Participate in the B. Riley Securities Virtual Oncology Conference
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
Geron to Participate at Upcoming Investor Conferences in November
From Geron Corporation
Via Business Wire
Tickers GERN
Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results
From Geron Corporation
Via Business Wire
Tickers GERN
Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting
From Geron Corporation
Via Business Wire
Tickers GERN
Geron to Participate in the Baird 2023 Global Healthcare Conference
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results
From Geron Corporation
Via Business Wire
Tickers GERN
Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients
From Geron Corporation
Via Business Wire
Tickers GERN
Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
From Geron Corporation
Via Business Wire
Tickers GERN
Geron to Host Virtual Investor Event on June 14, 2023
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS Patients
From Geron Corporation
Via Business Wire
Tickers GERN
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.